Skip to Main Content

Go to Main Navigation

Video: High Sensitivity TSO500 Detection

Small Scientist on November 10, 2020

On November 10, 2020, Discovery Life Sciences’ Dr. Shawn Levy — Chief Scientific Officer of Discovery Life Sciences’ sequencing and bioinformatics laboratory, HudsonAlpha Discovery — presented about some of their latest technologies.

He explained how Discovery Life Sciences has developed a new bundled solution leveraging Illumina’s TruSight Oncology 500 (TSO00) Solid Tumor (FFPE) and cfDNA that delivers actionable, reliable NGS data across matched FFPE tumor and plasma biospecimens and discussed how their services could be used to advance biomarker programs.

You can access the entire presentation recording below, including a very informative Q&A session.

If you have questions for Discovery Life Sciences, email them at or access their profile page on

Interested in hosting a webinar with Contact us at